As no consistent definition of clinical response is used between T1D intervention trials (17), those above the median slope across all treatment arms combined (ATG, ATG/G-CSF, and placebo) were considered responders, and those below the median slope were considered nonresponders (Figure 1). This evidence concerns the gene CSF3 and type 1 diabetes mellitus.